Growth hormone improves bone mineral content in children with cystic fibrosis

Dana S. Hardin, Chul Ahn, Claude Prestidge, Dan K. Seilheimer, Kenneth J. Ellis

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Aim: Osteoporosis and osteopenia have been reported as common complications of cystic fibrosis (CF); however, little is known about accrual of bone mineral in CF. The goal of our study was to measure bone mineral content (BMC) in non-acutely-ill, but poorly growing children with CF, and to determine the relationship between height, lean body mass and BMC. Our second aim was to evaluate the effect of one year of treatment with human recombinant growth hormone (GH) on total body BMC. Methods: We measured total-body BMC using dual energy X-ray absorptiometry in 32 poorly growing (height ≤10th percentile for age) prepubertal Caucasian children (ages 7 years 6 months-12 years 9 months, 17 M and 15, F) with CF. BMC and lean tissue mass (LTM) were measured at baseline, at 6 months and one year. One half of the children were randomly assigned to receive treatment with GH (GHTX). Results were compared to reference data maintained for healthy children matched for age and ethnicity. Sex steroid and IGF-I levels were also measured. Results: Children with CF exhibited lower total body BMC and LTM than age-, ethnicity- and gender-matched controls. This was still apparent when the data were matched for height and bone age. BMC correlated with height, LTM, and IGF-I levels. Although at baseline the groups were similar, the GHTX group demonstrated significantly greater increase in height, weight, LTM and BMC than the NonTX group. These differences remained despite correction for increase in height. Conclusion: Our study is the first to evaluate BMC in children with CF and suggests that poor accumulation of bone mineral is a problem. We have further demonstrated that GH treatment improves accumulation of bone mineral.

Original languageEnglish (US)
Pages (from-to)589-595
Number of pages7
JournalJournal of Pediatric Endocrinology and Metabolism
Volume18
Issue number6
StatePublished - Jun 2005

Fingerprint

Cystic Fibrosis
Bone Density
Growth Hormone
Minerals
Bone and Bones
Insulin-Like Growth Factor I
Body Height
Human Growth Hormone
Metabolic Bone Diseases
Photon Absorptiometry
Osteoporosis
Therapeutics
Steroids
Weights and Measures

Keywords

  • Bone mineral content
  • Cystic fibrosis
  • Growth hormone
  • Lean tissue mass
  • Osteopenia
  • Osteoporosis

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Hardin, D. S., Ahn, C., Prestidge, C., Seilheimer, D. K., & Ellis, K. J. (2005). Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology and Metabolism, 18(6), 589-595.

Growth hormone improves bone mineral content in children with cystic fibrosis. / Hardin, Dana S.; Ahn, Chul; Prestidge, Claude; Seilheimer, Dan K.; Ellis, Kenneth J.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 18, No. 6, 06.2005, p. 589-595.

Research output: Contribution to journalArticle

Hardin, DS, Ahn, C, Prestidge, C, Seilheimer, DK & Ellis, KJ 2005, 'Growth hormone improves bone mineral content in children with cystic fibrosis', Journal of Pediatric Endocrinology and Metabolism, vol. 18, no. 6, pp. 589-595.
Hardin, Dana S. ; Ahn, Chul ; Prestidge, Claude ; Seilheimer, Dan K. ; Ellis, Kenneth J. / Growth hormone improves bone mineral content in children with cystic fibrosis. In: Journal of Pediatric Endocrinology and Metabolism. 2005 ; Vol. 18, No. 6. pp. 589-595.
@article{817114268e1249ccb6929e90956f8c2e,
title = "Growth hormone improves bone mineral content in children with cystic fibrosis",
abstract = "Aim: Osteoporosis and osteopenia have been reported as common complications of cystic fibrosis (CF); however, little is known about accrual of bone mineral in CF. The goal of our study was to measure bone mineral content (BMC) in non-acutely-ill, but poorly growing children with CF, and to determine the relationship between height, lean body mass and BMC. Our second aim was to evaluate the effect of one year of treatment with human recombinant growth hormone (GH) on total body BMC. Methods: We measured total-body BMC using dual energy X-ray absorptiometry in 32 poorly growing (height ≤10th percentile for age) prepubertal Caucasian children (ages 7 years 6 months-12 years 9 months, 17 M and 15, F) with CF. BMC and lean tissue mass (LTM) were measured at baseline, at 6 months and one year. One half of the children were randomly assigned to receive treatment with GH (GHTX). Results were compared to reference data maintained for healthy children matched for age and ethnicity. Sex steroid and IGF-I levels were also measured. Results: Children with CF exhibited lower total body BMC and LTM than age-, ethnicity- and gender-matched controls. This was still apparent when the data were matched for height and bone age. BMC correlated with height, LTM, and IGF-I levels. Although at baseline the groups were similar, the GHTX group demonstrated significantly greater increase in height, weight, LTM and BMC than the NonTX group. These differences remained despite correction for increase in height. Conclusion: Our study is the first to evaluate BMC in children with CF and suggests that poor accumulation of bone mineral is a problem. We have further demonstrated that GH treatment improves accumulation of bone mineral.",
keywords = "Bone mineral content, Cystic fibrosis, Growth hormone, Lean tissue mass, Osteopenia, Osteoporosis",
author = "Hardin, {Dana S.} and Chul Ahn and Claude Prestidge and Seilheimer, {Dan K.} and Ellis, {Kenneth J.}",
year = "2005",
month = "6",
language = "English (US)",
volume = "18",
pages = "589--595",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "6",

}

TY - JOUR

T1 - Growth hormone improves bone mineral content in children with cystic fibrosis

AU - Hardin, Dana S.

AU - Ahn, Chul

AU - Prestidge, Claude

AU - Seilheimer, Dan K.

AU - Ellis, Kenneth J.

PY - 2005/6

Y1 - 2005/6

N2 - Aim: Osteoporosis and osteopenia have been reported as common complications of cystic fibrosis (CF); however, little is known about accrual of bone mineral in CF. The goal of our study was to measure bone mineral content (BMC) in non-acutely-ill, but poorly growing children with CF, and to determine the relationship between height, lean body mass and BMC. Our second aim was to evaluate the effect of one year of treatment with human recombinant growth hormone (GH) on total body BMC. Methods: We measured total-body BMC using dual energy X-ray absorptiometry in 32 poorly growing (height ≤10th percentile for age) prepubertal Caucasian children (ages 7 years 6 months-12 years 9 months, 17 M and 15, F) with CF. BMC and lean tissue mass (LTM) were measured at baseline, at 6 months and one year. One half of the children were randomly assigned to receive treatment with GH (GHTX). Results were compared to reference data maintained for healthy children matched for age and ethnicity. Sex steroid and IGF-I levels were also measured. Results: Children with CF exhibited lower total body BMC and LTM than age-, ethnicity- and gender-matched controls. This was still apparent when the data were matched for height and bone age. BMC correlated with height, LTM, and IGF-I levels. Although at baseline the groups were similar, the GHTX group demonstrated significantly greater increase in height, weight, LTM and BMC than the NonTX group. These differences remained despite correction for increase in height. Conclusion: Our study is the first to evaluate BMC in children with CF and suggests that poor accumulation of bone mineral is a problem. We have further demonstrated that GH treatment improves accumulation of bone mineral.

AB - Aim: Osteoporosis and osteopenia have been reported as common complications of cystic fibrosis (CF); however, little is known about accrual of bone mineral in CF. The goal of our study was to measure bone mineral content (BMC) in non-acutely-ill, but poorly growing children with CF, and to determine the relationship between height, lean body mass and BMC. Our second aim was to evaluate the effect of one year of treatment with human recombinant growth hormone (GH) on total body BMC. Methods: We measured total-body BMC using dual energy X-ray absorptiometry in 32 poorly growing (height ≤10th percentile for age) prepubertal Caucasian children (ages 7 years 6 months-12 years 9 months, 17 M and 15, F) with CF. BMC and lean tissue mass (LTM) were measured at baseline, at 6 months and one year. One half of the children were randomly assigned to receive treatment with GH (GHTX). Results were compared to reference data maintained for healthy children matched for age and ethnicity. Sex steroid and IGF-I levels were also measured. Results: Children with CF exhibited lower total body BMC and LTM than age-, ethnicity- and gender-matched controls. This was still apparent when the data were matched for height and bone age. BMC correlated with height, LTM, and IGF-I levels. Although at baseline the groups were similar, the GHTX group demonstrated significantly greater increase in height, weight, LTM and BMC than the NonTX group. These differences remained despite correction for increase in height. Conclusion: Our study is the first to evaluate BMC in children with CF and suggests that poor accumulation of bone mineral is a problem. We have further demonstrated that GH treatment improves accumulation of bone mineral.

KW - Bone mineral content

KW - Cystic fibrosis

KW - Growth hormone

KW - Lean tissue mass

KW - Osteopenia

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=21444449050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21444449050&partnerID=8YFLogxK

M3 - Article

C2 - 16042327

AN - SCOPUS:21444449050

VL - 18

SP - 589

EP - 595

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 6

ER -